Subjects ” General neurology
HealthDay News – A two-dose therapy of the recombinant nanoparticle vaccine NVX-CoV2373 (Novavax) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has an efficacy of 89, according to a study published online on June 30th 7 percent in adults, the New England Journal of Medicine.
Paul T. Heath, MBBS, of the University of London, and colleagues conducted a randomized phase 3 study in 33 UK sites in adults aged 18 to 84 years. A total of 15,187 participants randomly received two intramuscular 5 µg doses of NVX-CoV2373 or placebo 21 days apart in a 1: 1 ratio. The per-protocol efficacy population was 14,039 participants.
The researchers found that 10 and 96 participants in the vaccine and placebo groups, respectively, had reported infections with symptoms occurring at least seven days after the second dose; The effectiveness of the vaccine in this per-protocol effectiveness population was 89.7 percent. Among the 10 landmark cases in the vaccine group, there were no hospital admissions or deaths. There were five cases of serious infection, all in the placebo group. In a post-hoc analysis, the vaccine effectiveness was 86.3 and 96.4 percent against the B.1.1.7 (alpha) variant and against non-B.1.1.7 variants, respectively. The reactogenicity was generally mild and transient. The incidence of major adverse events was low and similar in both groups.
Continue reading
“A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7 percent protection against SARS-CoV-2 infection and demonstrated high efficacy against the B.1.1.7 variant” write the authors.
Several authors disclosed financial ties to Novavax, which makes the NVX-CoV2373 vaccine and is funding the study.
Summary / full text
Subjects:
COVID19 COVID19 Vaccine General Infectious Diseases General Neurology
Would you like to read more?
Please log in or register first to view this content.
Login Register
to open
Next post in General Neurology
Shut down
Close for more information about Novavax vaccine in two doses protects against SARS-CoV-2 infection
Loading… 
Close for more information about Novavax vaccine in two doses protects against SARS-CoV-2 infection
Loading…
Close for more information about Novavax vaccine in two doses protects against SARS-CoV-2 infection
Loading…
Close for more information about Novavax vaccine in two doses protects against SARS-CoV-2 infection
Loading…
Would you like to see more content from Neurology Advisor?
Register now for free to access unlimited clinical news with personalized daily tips for you, Full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Would you like to read more?
Please log in or register first to view this content.
Login Register
